Mumbai: Senores Pharmaceuticals reported a significant year-on-year surge in its Profit After Tax (PAT) for Q3FY26 increasing 105% to ₹34 crores even as the company’s shares plunged following the news. The shares have decreased mostly due to ongoing strategic developments at the company, as it is in the middle of completing its acquisition of Apnar Pharmaceutical, which is expected to close by Q2 FY27.
The company’s revenues increased 64% to ₹175 crores, heavily supported by its emerging markets business that grew about 48% on a year on year basis. The company’s EBITDA for the quarter was also at a healthy ₹ 54 crores, a 86% year-on-year growth.
Senores is looking forward to eventually expanding its portfolio, with 46 approved Abbreviated New Drug Applications (ANDAs) and 22 additional ANDAs under development in the coming years. The company has already acquired 75% of Apnar Pharma, with its business integration and scale-up happening faster than anticipated. Apnar’s 3 ANDAs are expected to launch by Q4 FY26, while another 2 are in the pipeline.
“We delivered a robust performance in Q3FY26, with Revenue growing by 64%. In the Regulated Markets, we launched two new ANDAs with 3 strengths during the quarter. We have 28 approved ANDAs available for launch. Additionally, we have 22 more molecules, involving 50+ strengths, at different stages of development. This gives us a healthy pipeline of products which are expected to be rolled out over the coming quarters. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharma. We have completed acquisition of 75% stake, with the balance 25% expected to be completed by Q2 FY27.
The integration and scale-up of the Apnar Pharma business is happening faster than expected. The acquisition enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO-CMO opportunities, positioning Senores for sustained growth.
Our Emerging Markets product portfolio continued to expand. We achieved our highest-ever quarterly Revenue and EBITDA in Emerging Markets in Q3 FY26. Strong product acceptance and customer adoption are driving this momentum. We are now approved and supplying to multiple large hospital chains across India. All in all, we have delivered a strong performance in the quarter and nine-months and remain on track to deliver on our full year guidance.” Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said in a press release.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Readers should conduct their own research or consult with a qualified financial advisor before making any investment decisions.
